Immunity & good health is determined by the collective presence of living symbiotic, and pathogenic microorganisms in the human microbiome system. Throughout the life cycle age accordingly, bacterial community & its characteristics vary.
Nasal cavity mutualistic bacteria compete for space, and nutrients & produce toxic materials, helping repress pathogenic bacteria and inhibit or kill them. Nasal cavity dysbiosis leads to opportunistic pathogenic bacteria presence, spread in the respiratory tract & the development of allergic rhinitis (AR), chronic rhinosinusitis (CRS), acute respiratory tract infections (ARTI), otitis media (OM), and asthma.
CRS
Instigates disease progression, nasal polyps’ development, chronic symptoms, and sinus cavity inflammatory response. The prevalent presence of Coagulase-negative Staphylococcus, Pseudomonas aeruginosa, and S. aureus influence & modulate the immune response.
Determines asthma onset, advancement, acuteness, metagenomic inference & bacterial glycerolipid metabolism and increase in Prevotella buccalis, Gardnerella vaginalis, P. buccalis, G. vaginalis, Dialister invisus, and Alkanindiges hongkongensis species. Asymptomatic expansion of Streptococcus affects the future possibility, danger & later episodes of asthma and its inflammation symptoms.
In asthma-affected children, Moraxella, Staphylococcus, Corynebacterium, Haemophilus, Fusobacterium, Prevotella, and Dolosigranulum dominate the nasal microbiome environment.
Affects the immune response modulation, pathophysiology & AR growth. In seasonal allergic rhinitis (SAR) patients, pollination season spikes symptoms, nasal eosinophils levels & middle meatus bacterial biodiversity.
Controls host’s susceptibility, influenza-specific immunoglobulin A antibody production disparity, taxa richness rise & the surge of Streptococcus pneumoniae, S. aureus, Phyllobacterium, Moraxella, Staphylococcus, Corynebacterium, and Dolosigranulum in the nasal carriage.
Concomitantly S. pneumoniae transmission increases shooting up protease secretion, activates viral hemagglutinins and modulates the innate immune response. Facilitates influenza, A virus (adenovirus, or rhinovirus) infection & associated respiratory virus infection, S. pneumoniae elevation & invasive pneumococcal pneumonia risk.
Regulates Moraxella, Streptococcus, and Pasteurella spp migration from the middle ear to the nose microbiome & leading to OM. S. pneumoniae, Haemophilus, Actinomyces, Rothia, Neisseria, and Veillonella increase in OM-affected children. OM acute episodes escalate abundant increase of otopathogen genera and decrease in Pseudomonas, Myroides, Yersinia, and Sphingomonas.
The nasal passage is colonized with a diverse range of bacteria, fungi, and viruses and it is the first contact point to the external environment exposure. The nasal microbiota profile positively correlates with amplified immune response. Further research is required to reinforce the promising role of probiotic intervention in the supplementary treatment of nasal dysbiosis-connected respiratory infections.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
2.
Study identifies new approach to protect the brain during radiation therapy
3.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
4.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
5.
Radiation therapy for patients with breast cancer
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Navigating the Complexities of Ph Negative ALL - Part XIII
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation